Search Results

You are looking at 1 - 10 of 333 items for :

  • pancreatic cancer x
Clear All
Open access

Marek Durlik and Katarzyna Gardian

References Raporty na podstawie danych Centrum Onkologii http://85.128.14.124/krn/ Singh P, Srinivasan R, Dev Wig J : Major Molecular Markers in Pancretic Ductal Adenocarcinoma and Their Roles in Screening, Diagnosis, Prognosis and Treatment, Pancreas 2011; 40: 644-52. Neoptolemos JP, Urrutia RA, Abbruzzese J et al.: Pancreatic cancer. Springer 2010. Egebald M, Werb Z : New functions for the matrix metalloproteinases in cancer progression. Nature Rev

Open access

M.I. Costache, Mihai Ioana, Sevastiţa Iordache, D. Ene, Cornelia Alexandra Costache and A. Săftoiu

renal cell carcinomas. Pathol Res Pract. 2014 Dec; 210 (12):901-8. 72. AI K.X., LU L.Y., HUANG X.Y., CHEN W., ZHANG H.Z. Prognostic significance of S100A4 and vascular endothelial growth factor expression in pancreatic cancer. World J Gastroenterol. 2008 Mar 28; 14 (12):1931-5. 73. VON MARSCHALL Z., CRAMER T., HÖCKER M., BURDE R., PLATH T., SCHIRNER M., HEIDENREICH R., BREIER G., RIECKEN E.O., WIEDENMANN B., ROSEWICZ S. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop

Open access

Ramona Crişan, Mihaela Aldea and Gabriel Kacso

References 1. Jamal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ . Cancer statistic, 2009. CA Cancer J Clin 59: 225-249, 2009. 2. Hsu C, Saif MW. Diabetes and pancreatic cancer. Highlights from the „2011 ASCO Annual Meeting” JOP 12: 330-333, 2011. 3. Huggett MT, Pereira SP . Diagnosing and managing pancreatic cancer. Practitioner 255: 21-25, 2-3, 2011. 4. DeCensi A, Puntoni M, Goodwin P et al . Metformin and cancer risk in diabetic patients: a systematic review and meta

Open access

Adam Durczyński, Dariusz Szymański, Michał Nowicki, Piotr Hogendorf, Grażyna Poznańska and Janusz Strzelczyk

References 1. Michaud DS : Epidemiology of pancreatic cancer. Minerva Chir 2004; 59(2): 99-111. 2. Kędra B, Popiela T, Sierzega M et al.: Prognostic factors of long-term survival after resective procedures for pancreatic cancer. Hepatogastroenterol 2001; 48(42): 1762-66. 3. Tomimaru Y, Yano M, Takachi K et al.: Plasma D-dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer. J Am Coll Surg 2006; 202: 139-45. 4. Yamashita H

Open access

Jakob Liermann, Patrick Naumann, Franco Fortunato, Thomas E. Schmid, Klaus-Josef Weber, Jürgen Debus and Stephanie E. Combs

Introduction Pancreatic cancer is the fourth leading cause of cancer related deaths in the United States. 1 Surgical resection is still the most important treatment modality and prognostic factor, but in the late stage of the disease, only 10–20% of all primary tumours are still operable. 2 Beside primary metastasized and thus palliative stage IV disease 30-40% of all cases are locally advanced but non-metastasized tumors that could benefit from neoadjuvant treatment. 3 We recently reported that approximately one third of these locally advanced tumors

Open access

Thilo Hackert, Markus Büchler and Jens Werner

References Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2007. CA Cancer J Clin 2007; 57(1): 43-66. Hariharan D, Saied A, Kocher HM : Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford) 2008; 10(1): 58-62. Wagner M, Redaelli C, Lietz M et al.: Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2005; 91: 586-94. Schnelldorfer T, Ware AL

Open access

Tomasz Stefaniak, Jacek Reszetow, Łukasz Żemojtel, Jarosłstrok;aw Kobiela, Wojciech Makarewicz, Łukasz Kaska, Jacek Krajewski, Monika Proczko-Markuszewska, Barbara Kwiecińska, Andrzej Łachiński, Andrzej Basiński and Zbigniew Śledziński

References Lebovits AH, Lefkowitz M : Pain management of pancreatic carcinoma: a review. Pain 1989; 36(1): 1-11. Freelove R, Walling AD : Pancreatic cancer: diagnosis and management. Am Fam Physician 2006; 73(3): 485-92. Okuyama M, Shibata T, Morita T et al.: A comparison of intraoperative celiac plexus block with pharmacological therapy as a treatment for pain of unresectable pancreatic cancer. J Hepatobiliary Pancreat Surg 2002; 9(3): 372

Open access

Z. Tajabadi, M. E. Akbari and A. A. Hafez

Med Sci Sports. 2009;19(6):764-81. 7. Wen XY. Salt taste sensitivity, physical activity and gastric cancer. APJCP. 2010;11(6):1473-7. 8. Chen Y, Yu C, Li Y. Physical activity and risks of esophageal and gastric cancers: a meta-analysis. PloS one. 2014;9(2):e88082. 9. Farris MS, Mosli MH, McFadden AA et al. The Association between Leisure Time Physical Activity and Pancreatic Cancer Risk in Adults: A Systematic Review and Meta-analysis. Cancer Epidemiol, Biomarkers Prev. 2015;24(10):1462-73. 10. Nothlings U, Wilkens LR, Murphy SP et al. Body

Open access

Piotr Kulig, Radosław Pach, Szymon Pietruszka, Bartłomiej Banaś, Marek Sierżęga and Piotr Kołodziejczyk

PR et al.: Imaging of pancreatic adenocarcinoma: update on staging/resectability. Radiol Clin North Am 2012; 50(3): 407-28. Bipat S, Phoa S, Van Delden O et al.: Ultrasonography, computer tomography and magnetic resonance imaging for diagnostic and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 2005; 29: 438-45. Greene FL, Page D, Fleming J et al.: Exocrine pancreas. AJCC Cancer Staging Manual. 6th ed. New York, NY. Springer 2002: 179

Open access

Krzysztof Szwedziak and Janusz Strzelczyk

References 1. Celiński K, Mądro A: Postępy w diagnostyce i leczeniu raka trzustki. Gastroenterol Pol 2005; 12: 341-46 2. Krejs GJ: Pancreatic cancer: epidemiology and risk factors. Dig Dis 2010; 28: 355-58. 3. Ballehaninna UK , Chamberlain RS: The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 2012; 3: 105-19. 4. Delbeke D, Pinson CW : Pancreatic tumors: role of